Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC LAGIPRA peptide (TFA) | 98.2% | 5756.50 (free base) | 5 MG
LAGIPRA peptide TFA is a long-acting GIP1R agonist that enhances insulin sensitivity by augmenting glucose disposal. It also reduces branched-chain amino acids (BCAAs) and ketoacids, making it a potential subject for research into type 2 diabetes.
- Long-acting GIP1R agonist
- Enhances insulin sensitivity by augmenting glucose disposal
- Reduces branched-chain amino acids (BCAAs) and ketoacids
- Potential for research into type 2 diabetes
Medchemexpress LLC CCZ01048 TFA | 98.5% | 1622.75 | 1 MG
CCZ01048 TFA is an α-MSH analogue that demonstrates high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. It rapidly internalizes into B16F10 melanoma cells and exhibits high in vivo stability, making it a promising candidate for PET imaging of malignant melanoma. The cationic Pip linker used in CCZ01048 improves tumor uptake and generates high tumor-to-normal tissue contrast in PET imaging within a preclinical melanoma model.
- Exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM
- Rapid internalization into B16F10 melanoma cells
- Shows high in vivo stability
- Promising candidate for PET imaging of malignant melanoma
- Cationic Pip linker improves tumor uptake
- Generates high tumor-to-normal tissue contrast with PET imaging in a preclinical melanoma model
Medchemexpress LLC Wd6305 Tfa | 99.8% | 1226.40 | 5 MG
WD6305 TFA is a potent and selective PROTAC degrader targeting METTL3-METTL14. It inhibits m6A modification and proliferation of AML cells, and induces apoptosis. This compound also exhibits antitumor activity.
- Potent and selective PROTAC degrader
- Targets METTL3 and METTL14
- Inhibits m6A modification
- Inhibits proliferation of AML cells
- Induces apoptosis
- Exhibits antitumor activity
Medchemexpress LLC APL180 TFA (L-4F TFA) | 98.8% | 2310.60 (free base) | 25 MG
APL180 TFA (L-4F) is an apolipoprotein AI mimetic peptide that enhances the anti-inflammatory activity of high-density lipoprotein (HDL). APL180 can be used in the study of cardiovascular diseases.
- Apolipoprotein AI mimetic peptide
- Enhances the anti-inflammatory activity of high-density lipoprotein (HDL)
- Can be used in the study of cardiovascular diseases
Medchemexpress LLC Alpha-Melanocyte-Stimulating Hormone TFA | 171869-93-5 | 98.5% | 1 MG
α-MSH TFA (α-Melanocyte-Stimulating Hormone TFA) is an endogenous neuropeptide and a melanocortin receptor 4 (MC4R) agonist. It exhibits anti-inflammatory and antipyretic activities and is a post-translational derivative of pro-opiomelanocortin (POMC).
- Endogenous neuropeptide
- MC4R agonist with anti-inflammatory and antipyretic activities
- Post-translational derivative of pro-opiomelanocortin (POMC)
- Modulates CNS inflammation by acting directly on melanocortin receptors in glial cells
- Modulates NFκB activation
- Inhibits translocation of transcription factor κB to the nucleus
Medchemexpress LLC Wp9qy Tfa | 99.4% | 1340.40 | 5 MG
WP9QY TFA is a biologically active cyclic peptide designed as a TNF-α antagonist. It mimics the critical tumor necrosis factor (TNF) recognition loop on TNF receptor I, thereby preventing interactions of TNF with its receptor. This makes it a useful template for developing small molecular inhibitors to prevent inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.
- Acts as a TNF-α antagonist
- Designed to mimic TNF recognition loop on TNF receptor I
- Prevents TNF interactions with its receptor
- Useful for developing inhibitors for inflammatory bone destruction
- Helps prevent systemic bone loss in rheumatoid arthritis
Medchemexpress LLC Huwentoxin-IV TFA | 105856-78-4 | 99.04% | 4099.71 | 5 MG
Huwentoxin-IV TFA is a highly potent and selective blocker of neuronal voltage-gated sodium channels. It specifically inhibits NaV1.7 activity in human DRG neurons.
- Potent and selective sodium channel blocker
- Inhibits neuronal NaV1.7, NaV1.2, NaV1.3, and NaV1.4 channels
- IC50 of 2.9 nM for inhibiting NaV1.7-mediated currents
- Reduces NaV1.7 current amplitude by 50% at 0.5 nM
Medchemexpress LLC LARLLT (TFA) | 99.9% | 799.88 | 5 MG
LARLLT (TFA) is an EGFR-binding peptide with potential for research into EGFR overexpressing cancers, including lung, ovarian, and colorectal cancer.
- EGFR-binding peptide
- Potential for research of EGFR overexpressing cancers
- Targets EGFR
- Involves JAK/STAT signaling and protein tyrosine kinase/RTK pathways
- Sequence: Leu-Ala-Arg-Leu-Leu-Thr
- Molecular weight of 799.88
- Purity of 99.9% (HPLC)
- Soluble in DMSO: 50 mg/mL
- Appears as a white to off-white solid
- Powder storage: -80°C for 2 years, -20°C for 1 year
- In solvent storage: -80°C for 6 months, -20°C for 1 month (sealed storage, away from moisture)
Medchemexpress LLC Tat-NR2B9c TFA | 1834571-04-8 | 99.7% | 2632.90 | 25 MG
Tat-NR2B9c TFA is a potent inhibitor of postsynaptic density-95 (PSD-95). It selectively disrupts the interaction between PSD-95 and NMDAR, inhibiting the binding of NR2A and NR2B to PSD-95. This compound also inhibits the interaction between neuronal nitric oxide synthase (nNOS) and PSD-95, demonstrating significant neuroprotective efficacy.
- Potent PSD-95 inhibitor with high affinity for PSD-95d2 (EC50 6.7 nM)
- Inhibits NMDAR2A, NMDAR2B, and NMDAR2C binding to PSD-95
- Blocks interaction between PSD-95 and nNOS
- Reduces infarction volume in vivo
Medchemexpress LLC GRGDSP TFA | 98.0% | 701.61 | 25 MG
GRGDSP (TFA) is an integrin inhibitor. This synthetic linear RGD peptide can inhibit the adherence of tumor cells to endothelial cells of blood vessels, thereby limiting metastasis. It is also utilized to modify the surface of cardiovascular implants, such as vascular grafts, to promote endothelialization, and is widely employed in integrin research as a soluble integrin-blocking RGD-based peptide.
- Inhibits adherence of tumor cells to endothelial cells of blood vessels
- Limits metastasis
- Promotes endothelialization for cardiovascular implants
- Used in integrin research
- Functions as a soluble integrin-blocking RGD-based peptide
Medchemexpress LLC KLD-12 TFA | 95.22% | 1467.79 | 5 MG
KLD-12 TFA is the TFA salt form of KLD-12, a 12-residue self-assembling peptide. It is used in tissue engineering and, when combined with SDF-1 self-assembled polypeptide, enhances chondrogenic differentiation of bone marrow stromal cells (BMSCs). The hydrogel form can fill full-thickness osteochondral defects in situ and improve cartilage repair. In vivo, it promotes bone regeneration at the fracture site in a dose-dependent manner.
- Enhances chondrogenic differentiation of bone marrow stromal cells
- Forms self-assembled polypeptide with SDF-1
- Improves survival of bone marrow stromal cells
- Promotes osteogenic differentiation of bone marrow stromal cells and cell migration via Wnt/β-catenin pathway
- Promotes bone regeneration at the fracture site
Medchemexpress LLC Cys-PKHB1 TFA | 65.8% | 1487.88 | 1 MG
Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, which is a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. This peptide induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. It also induces immune system activation in breast cancer cells through immunogenic cell death.
- Peptide conjugated to PKHB1
- Acts as a CD47 agonist
- Functions as a thrombospondin-1 peptide mimic
- Induces mitochondrial alterations
- Promotes ROS generation
- Leads to intracellular Ca+ accumulation
- Causes calcium-dependent cell death in breast cancer cells
- Induces immune system activation in breast cancer cells
Medchemexpress LLC WD6305 TFA | 99.8% | 1226.40 | 1 MG
WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. It has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 TFA inhibits m6A modification and proliferation of AML cells, and induces apoptosis. It also exhibits antitumor activity.
- Potent and selective PROTAC degrader.
- Inhibits m6A modification and proliferation of AML cells.
- Induces apoptosis.
- Has antitumor activity.
- For research use only.
Medchemexpress LLC IIQLPEIVVV TFA | 99.9% | 1122.40 | 1 MG
IIQLPEIVVV TFA is a specific inhibitor of Drp1-Mff interaction. It can distinguish physiological from pathological fission and block physiological fission, leading to mitochondrial dysfunction. It can be used in the study of Huntington's disease.
- Specific inhibitor of Drp1-Mff interaction
- Distinguishes physiological from pathological fission
- Blocks physiological fission
- Leads to mitochondrial dysfunction
- Used in the study of Huntington's disease
- Purity of 99.91%
- White to off-white solid appearance
- Sequence: Ile-Ile-Gln-Leu-Pro-Glu-Ile-Val-Val-Val
Medchemexpress LLC Api137 TFA | 1428789-03-0 | 2291.71 | 1 MG
Api137 is an antimicrobial peptide designed to interfere with bacterial growth by inhibiting translation. It achieves this by trapping release factors on the 70S ribosome after the nascent polypeptide chain has been hydrolyzed, thereby preventing protein synthesis.
- Antimicrobial activity: effectively interferes with bacterial growth
- Translation inhibition: specific action on protein synthesis by targeting ribosomal release factors
- Research use only: intended for research purposes
- TFA form availability: available in a TFA (trifluoroacetate) form